Insights
Insights From Our Experts
Articles
2026 CMS Proposed Rule: BFSF Changes and Potential Risks for Pharma Manufacturers
CMS released its 2026 Proposed Rule this summer, outlining payment and coverage policy updates for Medicare Part B and related programs. For pharmaceutical manufacturers, the most significant development is the long-awaited clarification on bona fide service…
Navigating OBBBA: Why a Strong GP Team is Essential for Pharma Compliance
On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was signed into law, marking a significant shift in Medicaid, Medicare, and federal drug pricing policy. While broad in scope, its provisions have direct consequences…
The Future of Personalized, Measurable MSL Engagement
In today’s complex healthcare landscape, Medical Science Liaisons (MSLs) are under pressure to deliver more than trusted relationships. They must provide personalized, data-driven engagement that creates measurable value. While 58% of healthcare professionals rank MSL interactions…
Rewriting the Rules of Pharma Commercialization: Why the AI Agency Is the Catalyst Life Sciences Has Been Waiting For
Scientific innovation is accelerating. But commercialization? It’s stuck in the past — fragmented, reactive and increasingly unsustainable. Learn why the AI Agency is the catalyst life sciences commercialization has been waiting for in this POV. Faruk Capan,…
Navigating the New EU HTA Landscape: Pamela Vo on Strategic Evidence Planning
In a recent pharmaphorum interview, EVERSANA’s Pamela Vo emphasized the importance of early strategic evidence planning under the EU’s new Health Technology Assessment Regulation (HTAR). With the Joint Clinical Assessment (JCA) streamlining clinical evaluations across member…
Redefining Field Deployment – Bridging “Share of Voice” with “Share of Influence” for Lasting Impact
In a pharmaceutical environment where promotional noise is louder than ever, there’s a strategic blueprint for cutting through the clutter to create meaningful impact and establish long-lasting brand loyalty among healthcare stakeholders. Sales representatives and television…
“Nothing changes if nothing changes.”
“Nothing changes if nothing changes.” Why an integrated commercialization platform with the amplified power of a direct-to-patient (DTP) channel is no longer an option. It’s a must. Two-thirds of drug launches fall short of revenue goals,…
EVERSANA & Google Cloud Bring AI Agency Concept to Life
EVERSANA is redefining the future of medical marketing with the launch of its groundbreaking AI Agency—an end-to-end solution developed in partnership with Google Cloud. This platform, unveiled at Google’s New York office recently, promises to deliver…
Evaluation of HTA Frameworks for In Vivo Diagnostics: Assessing Methodological Gaps and Implications for Market Access
Health technology assessments (HTAs) are crucial for market access and reimbursement of diagnostic innovations, yet current frameworks often fail to reflect the true value of in vivo diagnostics—such as molecular imaging (MI) tracers and contrast media…
Optimizing Product Commercialization in Today’s IDN Environment
Traditional sales models that rely solely on prescriber outreach or consumer advertising are no longer effective. With nearly 70% of U.S. physicians employed by Integrated Delivery Networks (IDNs), the way therapies are evaluated, approved, and accessed…